10984 related articles for article (PubMed ID: 11968172)
1. [Of mice and humans. Updates on susceptibility and tumor suppression of malignant melanoma].
Hautarzt; 2002 Jan; 53(1):88-9. PubMed ID: 11968172
[No Abstract] [Full Text] [Related]
2. [Alternative protein p19ARF: a genuine tumor suppressor gene].
Larsen CJ
Bull Cancer; 1998 Apr; 85(4):304-6. PubMed ID: 9752293
[TBL] [Abstract][Full Text] [Related]
3. Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma.
Peters G
J Natl Cancer Inst; 2008 Jun; 100(11):757-9. PubMed ID: 18505965
[No Abstract] [Full Text] [Related]
4. CDKN2A and MC1R analysis in amelanotic and pigmented melanoma.
Ghiorzo P; Pastorino L; Pizzichetta MA; Bono R; Queirolo P; Talamini R; Annessi G; Bruno W; Nasti S; Gargiulo S; Battistuzzi L; Sini MC; Palmieri G; Scarrà GB;
Melanoma Res; 2009 Jun; 19(3):142-5. PubMed ID: 19339902
[TBL] [Abstract][Full Text] [Related]
5. Impaired processing of DNA photoproducts and ultraviolet hypermutability with loss of p16INK4a or p19ARF.
Sarkar-Agrawal P; Vergilis I; Sharpless NE; DePinho RA; Rünger TM
J Natl Cancer Inst; 2004 Dec; 96(23):1790-3. PubMed ID: 15572761
[TBL] [Abstract][Full Text] [Related]
6. Genetic study of familial uveal melanoma: association of uveal and cutaneous melanoma with cutaneous and ocular nevi.
Smith JH; Padnick-Silver L; Newlin A; Rhodes K; Rubinstein WS
Ophthalmology; 2007 Apr; 114(4):774-9. PubMed ID: 17207529
[TBL] [Abstract][Full Text] [Related]
7. [Genetic basis of malignant melanoma].
Drewa G; Powierska-Czarny J
Postepy Hig Med Dosw; 1998; 52(4):367-80. PubMed ID: 9780757
[TBL] [Abstract][Full Text] [Related]
8. The INK4a/ARF locus and melanoma.
Sharpless E; Chin L
Oncogene; 2003 May; 22(20):3092-8. PubMed ID: 12789286
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
10. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures.
van Schanke A; van Venrooij GM; Jongsma MJ; Banus HA; Mullenders LH; van Kranen HJ; de Gruijl FR
Cancer Res; 2006 Mar; 66(5):2608-15. PubMed ID: 16510579
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
12. [Tumor suppression by cellular senescence: molecular link between aging and cancer].
Sugimoto M; Takahashi A; Hara E
Tanpakushitsu Kakusan Koso; 2006 Jan; 51(1):10-7. PubMed ID: 16416878
[No Abstract] [Full Text] [Related]
13. Vitamin D receptor variants and the malignant melanoma risk: a population-based study.
Gapska P; Scott RJ; Serrano-Fernandez P; Mirecka A; Rassoud I; Górski B; Cybulski C; Huzarski T; Byrski T; Nagay L; Maleszka R; Sulikowski M; Lubinski J; Debniak T
Cancer Epidemiol; 2009 Aug; 33(2):103-7. PubMed ID: 19679055
[TBL] [Abstract][Full Text] [Related]
14. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Clin Cancer Res; 2005 Apr; 11(8):2991-7. PubMed ID: 15837753
[TBL] [Abstract][Full Text] [Related]
15. Genetic and environmental factors in cutaneous malignant melanoma.
Bressac-de-Paillerets B; Avril MF; Chompret A; Demenais F
Biochimie; 2002 Jan; 84(1):67-74. PubMed ID: 11900878
[TBL] [Abstract][Full Text] [Related]
16. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
[TBL] [Abstract][Full Text] [Related]
17. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.
Edmunds SC; Kelsell DP; Hungerford JL; Cree IA
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):2845-51. PubMed ID: 12202501
[TBL] [Abstract][Full Text] [Related]
18. CDKN2 mutations in melanoma.
Dracopoli NC; Fountain JW
Cancer Surv; 1996; 26():115-32. PubMed ID: 8783570
[No Abstract] [Full Text] [Related]
19. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma.
Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P
Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633
[No Abstract] [Full Text] [Related]
20. Contribution of genetic factors for melanoma susceptibility in sporadic US melanoma patients.
Council ML; Gardner JM; Helms C; Liu Y; Cornelius LA; Bowcock AM
Exp Dermatol; 2009 May; 18(5):485-7. PubMed ID: 19320745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
